Cardiovascular Systems (CSII +15%) gains today after reporting a better-than-expected Q2 net loss of $0.28 per share, $0.05 wider than a year ago but nonetheless beating analyst expectations. Revenue climbed 28% Y/Y, as conversions to the company's Stealth 360 treatment for peripheral artery disease continued at a high rate, representing 93% of total device revenues for the quarter. Revenue from office-based labs also climbed at a double-digit pace.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs